Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AbbVie to acquire TeneoOne and multiple myeloma drug from Teneobio
The deal is made possible via AbbVie’s exercise of its exclusive right to purchase TeneoOne and TNB-383B. The acquisition option was part of a strategic alliance formed with
The deal is made possible via AbbVie’s exercise of its exclusive right to purchase TeneoOne and TNB-383B. The acquisition option was part of a strategic alliance formed with
The indication is for intravenous use of the drug in both adult and paediatric patients aged two years and above who are on systemic corticosteroids and need supplemental
Lecanemab is an experimental humanised antibody that targets amyloid beta aggregates known as protofibril. The drug was developed as part of a collaboration between Eisai and BioArctic. The
The demerger is scheduled to occur mid-next year. Before the separation, GSK is set to obtain a dividend of up to £8bn from Consumer Healthcare. With a portfolio
ViiV Healthcare has signed a global collaboration and license agreement with Halozyme Therapeutics to develop “ultra-long-acting” medicines for HIV. The deal gives exclusive access to Halozyme’s ENHANZE drug
The European Commission has purchased an additional 150 million Moderna’s Covid-19 vaccine doses, bringing its confirmed order commitment to 460 million doses. The deal also includes an option
Arrowhead Pharmaceuticals has signed a global collaboration and license agreement with Horizon Therapeutics for the development of RNA interference (RNAi) therapeutic, ARO-XDH. ARO-XDH is a discovery-stage investigational RNAi
Court of First Instance of Brussels has ordered AstraZeneca to deliver 50 million doses of its Covid-19 vaccine to Europe by 27 September this year. The court decided to
Established in 1998, Aldevron is headquartered in Fargo, North Dakota, US. The company produces plasmid DNA, mRNA and recombinant proteins used in vaccines, gene and cell therapy, gene editing
An investigational radioligand therapy, 177Lu-PSMA-617 is intended for precision cancer treatment. It is a combination of a targeting compound (ligand) and a therapeutic radioisotope. On administration into the